2.1
Crizotinib (Xalkori, Pfizer) is indicated for 'the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)'.
2 Information about crizotinib
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for crizotinib.
Price
2.3
The list price is £4,689.00 per 60‑capsule pack of 200 mg or 250 mg capsules (excluding VAT; BNF online accessed October 2024).
2.4
The company has a commercial arrangement. This makes crizotinib available to the NHS with a discount. The size of the discount is commercial in confidence.